A phase I trial of LY573636 administered as a 24-hour continuous infusion on day 1 of a 28-day cycle in patients with refractory solid tumors

Trial Profile

A phase I trial of LY573636 administered as a 24-hour continuous infusion on day 1 of a 28-day cycle in patients with refractory solid tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2006

At a glance

  • Drugs Tasisulam (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top